Asia Pacific Diabetes Devices Market Research Report - Segmented By Device Type (Glucose Monitoring Devices, Insulin Delivery Systems, Control Solutions) And Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis From 2026 to 2034
The Asia Pacific diabetes devices market size was valued at USD 3.64 billion in 2024 and is anticipated to reach USD 3.91 billion in 2026 from USD 6.93 billion by 2034, growing at a CAGR of 7.41% during the forecast period from 2026 to 2034
Diabetes is a group of metabolic disorders, a chronic condition that is associated with an abnormally high level of sugar (glucose) in the blood. Southeast Asia currently witnesses 78.3 million people affected with Diabetes, which is going to reach 140.2 million by 2040. The Western Pacific region witnesses 153.2 million people affected with diabetes, and this number is said to reach 214.8 million by 2040.
The Asia Pacific has the highest diabetes population, with the number increasing at quite an alarming rate. Due to this, there is a massive demand for diabetes care devices, primarily driving the market. Also, the increasing healthcare costs operate the market with increased revenues accumulated by the companies in this region.
But the market growth is constrained here due to the low medical literacy rate, leading to a fall in sales of devices.
| REPORT METRIC | DETAILS |
| Market Size Available | 2025 to 2034 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2034 |
| CAGR | 7.41% |
| Segments Covered | By Device Type, and Region |
| Various Analyses Covered | Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
| Countries Covered | India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, the Philippines, Indonesia, Singapore, and the Rest of APAC. |
| Market Leaders Profiled | Roche Diagnostics, Johnson & Johnson, Abbott Laboratories, Novo Nordisk, Ascensia, Tandem, and Terumo. |
Regionally, countries such as China, India, Japan, Korea, and Australia. China and India are the leading contributors in this region with a significant incidence of companies involved in manufacturing diabetes care devices, due to the highest prevalence of Diabetes population in their areas. China has the world’s largest community, with close to 1.4 billion people, followed by India, with around 1.2 billion people in 2014. According to the International Diabetes Federation, China had the most significant number of diabetic patients, with about 96.2 million diabetic patients followed by India, with around 66.8 million diabetic patients in 2014. It represents a majority of approximately 40-45% of the global diabetic population living in India and China, providing significant opportunities for the global diabetes care devices companies to invest in this region.
A few of the leading companies operating in the Asia Pacific diabetes devices market include
This research report on the APAC diabetes devices market has been segmented and sub-segmented into the following categories.
By Device Type
By Country
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region